Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort study
Article
[키워드] 95% CI
Ad26.COV2.S
Ad26.COV2.S vaccine
age
Analysis
anti-SARS-CoV-2
Anti-spike
antibody
Antibody Response
Antiretroviral therapy
approved
assays
BNT162b2
CD4+ T-cell
CD8+ T-cell
ChAdOx1-S
comparable
Concentration
conducted
Control
controls
COVID-19
defined
ELISPOT
Endpoint
Environment
Final
generally mild
geometric
HIV
HIV-negative
IFN-γ
immunogenic
immunogenicity
Increased
IQR
less
maintain
male
marker
median age
mRNA vaccination
mRNA vaccine
mRNA-1273
mRNA-based vaccines
Netherland
Netherlands
of BNT162b2
PLWH
predicted
primary endpoint
prospective cohort study
Public
reactogenicity
receiving
recipients
reduced
Registered
remained
required
response
SARS-CoV-2 antibody
SARS-CoV-2 IgG
SARS-CoV-2 spike peptide
SARS-CoV-2 vaccination
SARS-CoV-2 vaccine
secondary
Serious Adverse Events
serological response
Sex
suppressed
T-cell Response
the median
the vaccine
Trial
vaccination
Vaccine
vaccine group
Viral load
with HIV
[DOI] 10.1371/journal.pmed.1003979 PMC 바로가기
[DOI] 10.1371/journal.pmed.1003979 PMC 바로가기